Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1456 to 1470 of 1688 results for carers

  1. Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

    Discontinued [GID-TA10234]

  2. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

    In development [GID-TA10597] Expected publication date: TBC

  3. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued [GID-TA10739]

  4. Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417]

    Discontinued [GID-TA11522]

  5. Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]

    In development [GID-TA11580] Expected publication date: TBC

  6. Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease (MIB132)

    NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .

  7. Otovent nasal balloon for otitis media with effusion (MIB59)

    NICE has developed a medtech innovation briefing (MIB) on the Otovent nasal balloon for otitis media with effusion

  8. Emphysema - inhaled alpha-1 antitrypsin [ID1200]

    Discontinued [GID-TA11179]

  9. Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594

    In development [GID-TA11310] Expected publication date: TBC

  10. Two technologies recommended for people with chronic tic disorders and Tourette syndrome

    Draft guidance issued for consultation recommends two technologies to help people manage their condition.

  11. Bipolar, schizophrenia and other psychoses: care planning (IND143)

    This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a comprehensive care plan documented in the record, in the preceding 12 months, agreed between individuals, their family and/or carers as applicable. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM108

  12. Cardiovascular events (prevention, high risk) - anacetrapib [ID1164]

    Discontinued [GID-TA11176]

  13. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued [GID-HST10038]